학술논문
Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy.
Document Type
Article
Author
Roberts, Matthew J.; Morton, Andrew; Papa, Nathan; Franklin, Anthony; Raveenthiran, Sheliyan; Yaxley, William J.; Coughlin, Geoffrey; Gianduzzo, Troy; Kua, Boon; McEwan, Louise; Wong, David; Delahunt, Brett; Egevad, Lars; Samaratunga, Hemamali; Brown, Nicholas; Parkinson, Robert; Emmett, Louise; Yaxley, John W.
Source
Subject
*RADICAL prostatectomy
*GLEASON grading system
*PROSTATE biopsy
*BIOMARKERS
*PROGRESSION-free survival
*PROGNOSIS
*REGRESSION analysis
*
*
*
*
*
*
Language
ISSN
1619-7070
Abstract
Purpose: The prognostic value of PSMA intensity on PSMA PET/CT due to underlying biology and subsequent clinical implications is an emerging topic of interest. We sought to investigate whether primary tumour PSMA PET intensity contributes to pre- and post-operative prediction of oncological outcomes following radical prostatectomy. Methods: We performed a retrospective cohort study of 848 men who underwent all of multiparametric MRI (mpMRI), transperineal prostate biopsy, and 68 Ga-PSMA PET/CT prior to radical prostatectomy. PSMA intensity, quantified as maximum standard uptake value (SUVmax), and other clinical variables were considered relative to post-operative biochemical recurrence-free survival (BRFS) using Cox regression and Kaplan–Meier analysis. Results: After a median follow-up of 41 months, 219 events occurred; the estimated 3-year BRFS was 79% and the 5-year BRFS was 70%. Increasing PSMA intensity was associated with less favourable BRFS overall (Log rank p < 0.001), and within subgroups of Gleason score category (Log rank p < 0.03). PSMA intensity was significantly associated with shorter time to biochemical recurrence, after adjusting for pre-operative (HR per 5-unit SUVmax increase = 1.15) and post-operative (HR per 5-unit SUVmax increase = 1.10) parameters. Conclusion: These results in a large series of patients confirm PSMA intensity to be a novel, independent prognostic factor for BRFS. [ABSTRACT FROM AUTHOR]